A phase IB/IIA study of the safety and activity of intravenous isophosphoramide mustard (ZIO-201) in patients with advanced sarcoma

Trial Profile

A phase IB/IIA study of the safety and activity of intravenous isophosphoramide mustard (ZIO-201) in patients with advanced sarcoma

Completed
Phase of Trial: Phase I/II

Latest Information Update: 29 Jan 2014

At a glance

  • Drugs Palifosfamide (Primary)
  • Indications Osteosarcoma; Soft tissue sarcoma
  • Focus Adverse reactions
  • Sponsors ZIOPHARM Oncology
  • Most Recent Events

    • 17 Jul 2012 Additional lead trial investigator (Lewis J) added as reported by ClinicalTrials.gov.
    • 13 Oct 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 28 Nov 2008 New source identified and integrated (ZIOPHARM Oncology media release).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top